Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 3 of 3 entries
Sorted by: Best Match Show Resources per page
Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation.

British journal of clinical pharmacology

Arbel A, Abu-Ful Z, Preis M, Cohen S, Saliba W.
PMID: 33982796
Br J Clin Pharmacol. 2021 May 13; doi: 10.1111/bcp.14899. Epub 2021 May 13.

AIMS: Oral anticoagulants (OACs) are considered the mainstay in preventing stroke in atrial fibrillation (AF). OAC treatment remains suboptimal among AF patients, even after the introduction of direct oral anticoagulants (DOACs). We aimed to assess trends overtime and current...

Cite
Arbel A, Abu-Ful Z, Preis M, et al. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol. 2021;doi: 10.1111/bcp.14899.
Arbel, A., Abu-Ful, Z., Preis, M., Cohen, S., & Saliba, W. (2021). Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. British journal of clinical pharmacology, . https://doi.org/10.1111/bcp.14899
Arbel, Anat, et al. "Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation." British journal of clinical pharmacology vol. (2021). doi: https://doi.org/10.1111/bcp.14899
Arbel A, Abu-Ful Z, Preis M, Cohen S, Saliba W. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol. 2021 May 13; doi: 10.1111/bcp.14899. Epub 2021 May 13. PMID: 33982796.
Copy Download .nbib Format: NLM
Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation.

British journal of clinical pharmacology

Arbel A, Abu-Ful Z, Preis M, Cohen S, Saliba W.
PMID: 33982796
Br J Clin Pharmacol. 2021 Dec;87(12):4747-4755. doi: 10.1111/bcp.14899. Epub 2021 May 29.

AIMS: Oral anticoagulants (OACs) are considered the mainstay in preventing stroke in atrial fibrillation (AF). OAC treatment remains suboptimal among AF patients, even after the introduction of direct oral anticoagulants (DOACs). We aimed to assess trends overtime and current...

Cite
Arbel A, Abu-Ful Z, Preis M, et al. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol. 2021;87(12):4747-4755doi: 10.1111/bcp.14899.
Arbel, A., Abu-Ful, Z., Preis, M., Cohen, S., & Saliba, W. (2021). Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. British journal of clinical pharmacology, 87(12), 4747-4755. https://doi.org/10.1111/bcp.14899
Arbel, Anat, et al. "Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation." British journal of clinical pharmacology vol. 87,12 (2021): 4747-4755. doi: https://doi.org/10.1111/bcp.14899
Arbel A, Abu-Ful Z, Preis M, Cohen S, Saliba W. Implementation of oral anticoagulation treatment guidelines in patients with newly diagnosed atrial fibrillation. Br J Clin Pharmacol. 2021 Dec;87(12):4747-4755. doi: 10.1111/bcp.14899. Epub 2021 May 29. PMID: 33982796.
Copy Download .nbib Format: NLM
Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study.

The Lancet regional health. Europe

Shibli R, Barnett O, Abu-Full Z, Gronich N, Najjar-Debbiny R, Doweck I, Rennert G, Saliba W.
PMID: 34751262
Lancet Reg Health Eur. 2021 Dec;11:100236. doi: 10.1016/j.lanepe.2021.100236. Epub 2021 Nov 04.

BACKGROUND: An excess risk of Bell's palsy has been suggested after mRNA vaccines. We examined the association between the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy.METHODS: Using the database of the largest healthcare provider in Israel, we retrieved data...

Cite
Shibli R, Barnett O, Abu-Full Z, et al. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study. Lancet Reg Health Eur. 2021;11:100236doi: 10.1016/j.lanepe.2021.100236.
Shibli, R., Barnett, O., Abu-Full, Z., Gronich, N., Najjar-Debbiny, R., Doweck, I., Rennert, G., & Saliba, W. (2021). Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study. The Lancet regional health. Europe, 11100236. https://doi.org/10.1016/j.lanepe.2021.100236
Shibli, Rana, et al. "Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study." The Lancet regional health. Europe vol. 11 (2021): 100236. doi: https://doi.org/10.1016/j.lanepe.2021.100236
Shibli R, Barnett O, Abu-Full Z, Gronich N, Najjar-Debbiny R, Doweck I, Rennert G, Saliba W. Association between vaccination with the BNT162b2 mRNA COVID-19 vaccine and Bell's palsy: a population-based study. Lancet Reg Health Eur. 2021 Dec;11:100236. doi: 10.1016/j.lanepe.2021.100236. Epub 2021 Nov 04. PMID: 34751262; PMCID: PMC8566165.
Copy Download .nbib Format: NLM
Showing 1 to 3 of 3 entries